Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
Status:
Terminated
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if vorinostat combined with low-dose total skin
electron beam therapy (TSEBT) offers superior clinical benefit (efficacy & safety) over
low-dose TSEBT alone in participants with mycosis fungoides (MF)
Treatment in this study is TSEBT +/- vorinostat, with participants stratified by MF stage.